Catalent (NYSE:CTLT) PT Raised to $63.00 at Barclays

Catalent (NYSE:CTLT) had its target price hoisted by Barclays from $47.00 to $63.00 in a research note released on Friday, Benzinga reports. The brokerage currently has an equal weight rating on the stock.

Several other brokerages have also recently issued reports on CTLT. Stephens reaffirmed an equal weight rating and set a $63.50 price objective on shares of Catalent in a report on Thursday, April 4th. StockNews.com began coverage on Catalent in a report on Saturday, June 22nd. They set a sell rating for the company. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of Hold and an average price target of $55.65.

Catalent Trading Down 0.3 %

NYSE CTLT opened at $56.23 on Friday. The stock has a market capitalization of $10.18 billion, a P/E ratio of -9.22 and a beta of 1.20. Catalent has a 52-week low of $31.80 and a 52-week high of $60.20. The firm has a 50-day moving average price of $55.56 and a 200 day moving average price of $53.96. The company has a quick ratio of 1.77, a current ratio of 2.51 and a debt-to-equity ratio of 1.37.

Catalent (NYSE:CTLT) last issued its earnings results on Wednesday, May 8th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.21 by ($0.36). The company had revenue of $1.07 billion during the quarter, compared to analysts’ expectations of $1.11 billion. Catalent had a negative net margin of 26.61% and a negative return on equity of 2.73%. Equities research analysts expect that Catalent will post -0.17 EPS for the current year.

Insider Transactions at Catalent

In other news, insider Ricky Hopson sold 1,401 shares of Catalent stock in a transaction on Tuesday, June 4th. The stock was sold at an average price of $54.26, for a total value of $76,018.26. Following the completion of the sale, the insider now owns 20,617 shares of the company’s stock, valued at $1,118,678.42. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 0.31% of the company’s stock.

Institutional Investors Weigh In On Catalent

Institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its position in Catalent by 1.8% during the third quarter. Vanguard Group Inc. now owns 20,468,027 shares of the company’s stock valued at $931,909,000 after acquiring an additional 365,648 shares during the period. Tran Capital Management L.P. boosted its position in shares of Catalent by 12.2% in the fourth quarter. Tran Capital Management L.P. now owns 361,846 shares of the company’s stock worth $16,258,000 after buying an additional 39,208 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Catalent by 29.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,639,197 shares of the company’s stock worth $73,655,000 after buying an additional 376,931 shares during the period. SG Americas Securities LLC boosted its position in shares of Catalent by 240.0% in the fourth quarter. SG Americas Securities LLC now owns 40,249 shares of the company’s stock worth $1,808,000 after buying an additional 28,410 shares during the period. Finally, UBS Group AG boosted its position in shares of Catalent by 2.6% in the fourth quarter. UBS Group AG now owns 726,563 shares of the company’s stock worth $32,644,000 after buying an additional 18,752 shares during the period.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.